Sanofi-Aventis completes buyout of Genzyme
Sanofi-Aventis said Friday it has completed its $20.1 billion buyout of specialty drugmaker Genzyme Corp.
Sanofi-aventis announced on January 24 that it has extended its tender offer for all outstanding shares of common stock of Genzyme Corporation at $69.00 per share, net to the seller in cash, without interest and less any required withholding taxes.